Cargando…

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection

There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamora, Francis J, Dowers, Ellen, Yasin, Faiza, Ogbuagu, Onyema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817767/
https://www.ncbi.nlm.nih.gov/pubmed/31749636
http://dx.doi.org/10.2147/HIV.S216067
_version_ 1783463493064720384
author Zamora, Francis J
Dowers, Ellen
Yasin, Faiza
Ogbuagu, Onyema
author_facet Zamora, Francis J
Dowers, Ellen
Yasin, Faiza
Ogbuagu, Onyema
author_sort Zamora, Francis J
collection PubMed
description There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will become much more tolerable and less complicated for patients. In addition, and appropriately, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy. One of such approaches includes 2-drug regimen constructs that contain and retain effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options.
format Online
Article
Text
id pubmed-6817767
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68177672019-11-20 Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection Zamora, Francis J Dowers, Ellen Yasin, Faiza Ogbuagu, Onyema HIV AIDS (Auckl) Review There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will become much more tolerable and less complicated for patients. In addition, and appropriately, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy. One of such approaches includes 2-drug regimen constructs that contain and retain effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options. Dove 2019-10-23 /pmc/articles/PMC6817767/ /pubmed/31749636 http://dx.doi.org/10.2147/HIV.S216067 Text en © 2019 Zamora et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zamora, Francis J
Dowers, Ellen
Yasin, Faiza
Ogbuagu, Onyema
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_full Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_fullStr Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_full_unstemmed Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_short Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_sort dolutegravir and lamivudine combination for the treatment of hiv-1 infection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817767/
https://www.ncbi.nlm.nih.gov/pubmed/31749636
http://dx.doi.org/10.2147/HIV.S216067
work_keys_str_mv AT zamorafrancisj dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection
AT dowersellen dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection
AT yasinfaiza dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection
AT ogbuaguonyema dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection